Skip to main content
Premium Trial:

Request an Annual Quote

Bionomics and Neurofit and Beckman Coulter and pION

Premium

Bionomics to Acquire CRO Neurofit for $1.65M; CNS Tx Development Planned

Bionomics will acquire Neurofit, a French contract research organization, in a €1.25 million ($1.65 million) cash-and-stock transaction expected to close before March 1, the Adelaide, Australia-based company said last week.

Bionomics will pay €1 million in cash and €250,000 in shares for Strasbourg, France-based Neurofit. The company conducts preclinical testing of developmental therapeutics for CNS disorders using cellular and animal models, and lists Novartis, Serono, Boehringer-Ingelheim, and Biogen as clients.

The acquisition will enhance Bionomics’ therapeutic development capacity for CNS disorders, Bionomics said.

Additionally, the acquisition includes intellectual property rights to an animal model of Parkinson’s disease, developed by Institute Pasteur, and other animal models.

Earlier this year, Bionomics inked an agreement with PerkinElmer to collaborate on drug screening programs against ion channel and G-protein coupled receptor targets (see Inside Bioassays, 5/18/2004).


Beckman Coulter, Pion Pen Distribution Pact for Drug Permeability-analysis Instruments

Beckman Coulter has entered into a five-year distribution pact with pION to deliver instruments for the automation of in vitro drug-permeability instruments, Beckman Coulter said last week.

The firms will combine Beckman Coulter’s Biomek FX liquid handling system with pION’s double-sink method for parallel artificial membrane permeability analysis. The new instrument, called Biomek FX-ADME/tox Workstation, is controlled by software developed by Woburn, Mass.-based pION.

Beckman has validated the automated system and will distribute it worldwide. The firms will collaborate on application-specific customer support and training.

Financial terms of the deal were not disclosed.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.